The effects of fulvestrant, an estrogen receptor antagonist, on the proliferation, differentiation and mineralization of osteoprecursor cells

Park,Jun-Beom

doi:10.3892/mmr.2012.1200

The effects of fulvestrant, an estrogen receptor antagonist, on the proliferation, differentiation and mineralization of osteoprecursor cells

Authors:
- Jun-Beom Park
View Affiliations

Affiliations: Department of Periodontics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea
Published online on: November 23, 2012 https://doi.org/10.3892/mmr.2012.1200
Pages: 555-558

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fulvestrant is a novel type of endocrine treatment and is considered to be a potent inhibitor of breast cancer cell proliferation. Fulvestrant is reported to work by downregulating as well as degrading the estrogen receptor, leading to an inhibition of estrogen signaling through the estrogen receptor. The effects of various doses of fulvestrant for bone cells have not yet been fully investigated. In the present study, the effects of fulvestrant on osteoprecursor cells were evaluated. The effect on cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and protein measurement. Differentiation and mineralization were examined using an alkaline phosphatase activity (ALP) test and Alizarin red S staining. The protein expression of osteocalcin was evaluated using western blot analysis. Cultures grown in the presence of fulvestrant at concentrations of 0.1-10 µM did not show any significant change in cell proliferation. Cultures grown in the presence of fulvestrant showed a dose-dependent reduction in ALP activity, however, statistically significant differences were not achieved. Cultures grown in the presence of fulvestrant presented with a dose-dependent reduction in mineralization with a statistically significant difference at the 10 µM concentration. The use of fulvestrant may produce negative effects on the mineralization of osteoprecursor cells, while long-term use of fulvestrant may have detrimental effects on osteoblastic activity.

View Figures

View References

1	Dechering K, Boersma C and Mosselman S: Estrogen receptors alpha and beta: two receptors of a kind? Curr Med Chem. 7:561–576. 2000. View Article : Google Scholar : PubMed/NCBI
2	Song C, Wang J, Song Q, et al: Simvastatin induces estrogen receptor-alpha (ER-alpha) in murine bone marrow stromal cells. J Bone Miner Metab. 26:213–217. 2008. View Article : Google Scholar : PubMed/NCBI
3	Park JB: Effects of low dose of estrone on the proliferation, differentiation and mineralization of osteoprecursor cells. Exp Ther Med. 4:681–684. 2012.PubMed/NCBI
4	Dauvois S, Danielian PS, White R and Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA. 89:4037–4041. 1992. View Article : Google Scholar : PubMed/NCBI
5	Curran M and Wiseman L: Fulvestrant. Drugs. 61:807–814. 2001. View Article : Google Scholar : PubMed/NCBI
6	Osborne CK, Wakeling A and Nicholson RI: Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 90(Suppl 1): S2–S6. 2004. View Article : Google Scholar : PubMed/NCBI
7	Fawell SE, White R, Hoare S, Sydenham M, Page M and Parker MG: Inhibition of estrogen receptor-DNA binding by the ‘pure’ antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA. 87:6883–6887. 1990.
8	Nicholson RI, Gee JM, Manning DL, Wakeling AE, Montano MM and Katzenellenbogen BS: Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann NY Acad Sci. 761:148–163. 1995. View Article : Google Scholar : PubMed/NCBI
9	Brennan O, O’Brien FJ and McNamara LM: Estrogen plus estrogen receptor antagonists alter mineral production by osteoblasts in vitro. Horm Metab Res. 44:47–53. 2012. View Article : Google Scholar : PubMed/NCBI
10	Lykkesfeldt AE, Larsen SS and Briand P: Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer. 61:529–534. 1995. View Article : Google Scholar : PubMed/NCBI
11	de Cupis A, Noonan D, Pirani P, Ferrera A, Clerico L and Favoni RE: Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells. Br J Pharmacol. 116:2391–2400. 1995.
12	Robinson JA, Harris SA, Riggs BL and Spelsberg TC: Estrogen regulation of human osteoblastic cell proliferation and differentiation. Endocrinology. 138:2919–2927. 1997.PubMed/NCBI
13	Park JB, Zhang H, Lin CY, et al: Simvastatin maintains osteoblastic viability while promoting differentiation by partially regulating the expressions of estrogen receptors α. J Surg Res. 174:278–283. 2012.PubMed/NCBI
14	Park JB: The effects of dexamethasone, ascorbic acid, and β-glycerophosphate on osteoblastic differentiation by regulating estrogen receptor and osteopontin expression. J Surg Res. 173:99–104. 2012.
15	Park JB: Combination of simvastatin and bone morphogenetic protein-2 enhances differentiation of osteoblasts by regulating the expression of phospho-Smad1/5/8. Exp Ther Med. 4:303–306. 2012.PubMed/NCBI
16	Park JB: Effects of fibroblast growth factor 2 on osteoblastic proliferation and differentiation by regulating bone morphogenetic protein receptor expression. J Craniofac Surg. 22:1880–1882. 2011. View Article : Google Scholar : PubMed/NCBI
17	Park JB: Effects of doxycycline, minocycline, and tetracycline on cell proliferation, differentiation, and protein expression in osteoprecursor cells. J Craniofac Surg. 22:1839–1842. 2011. View Article : Google Scholar : PubMed/NCBI
18	Almazin SM, Dziak R, Andreana S and Ciancio SG: The effect of doxycycline hyclate, chlorhexidine gluconate, and minocycline hydrochloride on osteoblastic proliferation and differentiation in vitro. J Periodontol. 80:999–1005. 2009. View Article : Google Scholar : PubMed/NCBI
19	Fotakis G and Timbrell JA: In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett. 160:171–177. 2006. View Article : Google Scholar : PubMed/NCBI
20	Qu Q, Perälä-Heape M, Kapanen A, et al: Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone. 22:201–209. 1998. View Article : Google Scholar : PubMed/NCBI
21	Qi H, Aguiar DJ, Williams SM, La Pean A, Pan W and Verfaillie CM: Identification of genes responsible for osteoblast differentiation from human mesodermal progenitor cells. Proc Natl Acad Sci USA. 100:3305–3310. 2003. View Article : Google Scholar : PubMed/NCBI
22	Quarles LD, Yohay DA, Lever LW, Caton R and Wenstrup RJ: Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res. 7:683–692. 1992. View Article : Google Scholar : PubMed/NCBI
23	Gallagher A, Chambers TJ and Tobias JH: The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology. 133:2787–2791. 1993.PubMed/NCBI
24	Sato K, Nohtomi K, Shizume K, et al: 17 beta-estradiol increases calcium content in fetal mouse parietal bones cultured in serum-free medium only at physiological concentrations. Bone. 19:213–221. 1996. View Article : Google Scholar
25	Wakeling AE: The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat. 25:1–9. 1993. View Article : Google Scholar : PubMed/NCBI